Literature DB >> 9278300

The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)-dependent and TAP-independent peptide epitopes by class I molecules.

A Bai1, J Forman.   

Abstract

Cells were treated with two proteolytic inhibitors, N-acetyl-leucyl-leucyl-norleucinal and lactacystin, the latter reported to be a specific inhibitor for the proteasome. Both inhibitors retarded the maturation of endo-H-resistant forms of murine and human class I molecules from their endo-H-sensitive precursors in cell lines with functional TAP proteins. HLA-A2 maturation readily occurs in TAP-deficient T2 cells, and it has been shown that the peptides associated with A2 are derived from the leader segment of proteins in the secretory pathway. This maturation is inhibited by N-acetyl-leucyl-leucyl-norleucinal but not lactacystin, indicating that the proteasome is not required for the generation of HLA-A2 binding peptides in these cells. The murine class Ib molecule Qa-1b presents a leader peptide derived from D-end class I molecules to alloreactive CTL. Since this presentation is dependent on the expression of TAP proteins, we determined if this requirement reflects a need for the proteasome to process this peptide. We found that lactacystin did not inhibit the maturation of endo-H-resistant forms of Qa-1b that are dependent on this leader peptide for its maturation, nor did it inhibit the expression of this peptide-Qa-1b complex in a functional assay. Thus, unlike conventional cytosolic peptides, leader peptides (regardless of whether they are dependent on TAP for their presentation) do not require the proteasome for processing.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9278300

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses.

Authors:  K Schwarz; R de Giuli; G Schmidtke; S Kostka; M van den Broek; K B Kim; C M Crews; R Kraft; M Groettrup
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

2.  Intrasequence GFP in class I MHC molecules, a rigid probe for fluorescence anisotropy measurements of the membrane environment.

Authors:  Jonathan V Rocheleau; Michael Edidin; David W Piston
Journal:  Biophys J       Date:  2003-06       Impact factor: 4.033

3.  Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.

Authors:  Jonathan D Finn; Daniel Hui; Harre D Downey; Danielle Dunn; Gary C Pien; Federico Mingozzi; Shangzhen Zhou; Katherine A High
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

4.  Physical association of the K3 protein of gamma-2 herpesvirus 68 with major histocompatibility complex class I molecules with impaired peptide and beta(2)-microglobulin assembly.

Authors:  Y Y Lawrence Yu; Michael R Harris; Lonnie Lybarger; Lisa A Kimpler; Nancy B Myers; Herbert W Virgin; Ted H Hansen
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

5.  Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.

Authors:  Jumei Shi; Guido J Tricot; Tarun K Garg; Priyangi A Malaviarachchi; Susann M Szmania; Rachel E Kellum; Brian Storrie; Arend Mulder; John D Shaughnessy; Bart Barlogie; Frits van Rhee
Journal:  Blood       Date:  2007-10-18       Impact factor: 22.113

6.  Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.

Authors:  Guang Yang; Minjie Gao; Yiwen Zhang; Yuanyuan Kong; Lu Gao; Yi Tao; Ying Han; Huiqun Wu; Xiuqin Meng; Hongwei Xu; Fenghuang Zhan; Xiaosong Wu; Jumei Shi
Journal:  Oncotarget       Date:  2015-09-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.